TP508: a novel nuclear countermeasure targeting endothelial cells and stem cellsto combat ARS and delayed multiple organ dysfunction

Ended Definitive Contract Awarded Last action

Contract number
HHSN272201700011C
Awardee
Awarding agency
Obligated
$6,954,509

Award facts

Opportunity
Contract value 100% obligated
$6,954,508.60 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 29 offers Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
Galveston, TX 77550, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Funding Only Action P00017 · Deobligate funds from line item. -$0
Other Administrative Action P00016 $0
Other Administrative Action P00015 $0
Other Administrative Action P00014 · A novel nuclear countermeasure targeting endothelial cells and stem cellsto combat ARS and delayed multiple organ dysfunction $0
Other Administrative Action P00013 · Supplemental work - sars-COV-2 preclinical work $0
Supplemental Agreement for work within scope P00012 · Supplemental work-sars-COV-2 option - aim 5 $587,995
Other Administrative Action P00011 · Covid-19:supplemental work-sars-COV-2 - preclinical work $912,157
Other Administrative Action P00010 · To modify article B.2. And article F.1. $0
Other Administrative Action P00009 · To modify articles B.2. And I.3. $0
Other Administrative Action P00008 · To revise article B.3. Advance understandings, subcontract $0
Other Administrative Action P00007 · Revise article B.3. Advance understandings, subcontract $0
Exercise an Option P00006 · TP508: exercise option 2 period: assess the effect of TP508 $1,864,898
Other Administrative Action 5 · To 1) revise article B.3., advance understandings, subparagraph a., subcontracts, and 2) update article C.2. Reporting requirements. $0
Other Administrative Action 4 $0
Other Administrative Action 3 $0
Exercise an Option 2 $1,984,084
Other Administrative Action 1 $0
Original award $1,605,375
Show all 18

About this award

Written by GovTribe AI ·

This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Chrysalis Biotherapeutics, Inc. The contract is for "A NOVEL NUCLEAR COUNTERMEASURE TARGETING ENDOTHELIAL CELLS AND STEM CELLSTO COMBAT ARS AND DELAYED MULTIPLE ORGAN DYSFUNCTION" and has a ceiling value of $6,954,508.60. The contract is a Definitive Contract with a Cost Plus Fixed Fee pricing type and has an ultimate completion date of August 31, 2021. The contract was awarded on January 30, 2017 and does not have a set-aside designation.

Quick answers

Who was awarded contract HHSN272201700011C?

HHSN272201700011C was awarded to Chrysalis Biotherapeutics, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on January 30, 2017.

How much is contract HHSN272201700011C worth?

The government has obligated $6,954,509 on HHSN272201700011C.

Was contract HHSN272201700011C competed?

The extent of competition for HHSN272201700011C was full and open competition. The government received 29 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login